Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER -positive breast cancer (FAKTION): a randomized, double-blind, placebo-controlled, phase II trial
Jones, RH Carucci, M Casbard, AC Butler, R Alchami, F Bale, CJ Bezecny, P Joffe, J Moon, S Twelves, C
Jones, RH
Carucci, M
Casbard, AC
Butler, R
Alchami, F
Bale, CJ
Bezecny, P
Joffe, J
Moon, S
Twelves, C
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Jones RH, Carucci M, Casbard AC, Butler R, Alchami F, Bale CJ, et al. Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): a randomized, double-blind, placebo-controlled, phase II trial. J Clin Oncol. 2019;37(15_suppl):1005-.